Abstract:Background As the crosstalk between metabolism and antitumor immunity continues to be unraveled, we aim to develop a prognostic gene signature that integrates lipid metabolism and immune features for patients with lung adenocarcinoma (LUAD). Methods First, differentially expressed genes (DEGs) related to lipid metabolism in LUAD were detected, and subgroups of LUAD patients were identified via the unsupervised clustering method. Based on lipid metabolism and immune-related DEGs, variables were determined by the univariate Cox and LASSO regression, and a prognostic signature was established. The prognostic value of the signature was evaluated by the Kaplan–Meier method, time-dependent ROC, and univariate and multivariate analyses. Five independent GEO datasets were employed for external validation. Gene set enrichment analysis (GSEA), gene set variation analysis (GSVA), and immune infiltration analysis were performed to investigate the underlying mechanisms. The sensitivity to common chemotherapeutic drugs was estimated based on the GDSC database. Finally, we selected PSMC1 involved in the signature, which has not been reported in LUAD, for further experimental validation. Results LUAD patients with different lipid metabolism patterns exhibited significant differences in overall survival and immune infiltration levels. The prognostic signature incorporated 10 genes and stratified patients into high- and low-risk groups by median value splitting. The areas under the ROC curves were 0.69 (1-year), 0.72 (3-year), 0.74 (5-year), and 0.74 (10-year). The Kaplan–Meier survival analysis revealed a significantly poorer overall survival in the high-risk group in the TCGA cohort ( p < 0.001). In addition, both univariate and multivariate Cox regression analyses indicated that the prognostic model was the individual factor affecting the overall survival of LUAD patients. Through GSEA and GSVA, we found that tumor progression and inflammatory and immune-related pathways were enriched in the high-risk group. Additionally, patients with high-risk scores showed higher sensitivity to chemotherapeutic drugs. The in vitro experiments further confirmed that PSMC1 could promote the proliferation and migration of LUAD cells. Conclusions We developed and validated a novel signature incorporating both lipid metabolism and immune-related genes for all-stage LUAD patients. This signature can be applied not only for survival prediction but also for guiding personalized chemotherapy and immunotherapy regimens.

A novel gene signature related to fatty acid metabolism predicts prognosis, immune landscape, and drug sensitivity in early-stage lung squamous cell carcinoma

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

A novel gene signature related to focal adhesions for distinguishing and predicting the prognosis of lung squamous cell carcinoma

A novel signature incorporating genes related to lipid metabolism and immune for prognostic and functional prediction of breast cancer

A novel telomere-related gene prognostic signature for survival and drug treatment efficiency prediction in lung adenocarcinoma

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma

A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis

Comprehensive Analysis of a Novel Immune-Related Gene Signature in Lung Adenocarcinoma

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

A Novel Gene Signature Based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients

A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma

Characterization of a ferroptosis-related gene signature predicting survival and immunotherapeutic response in lung adenocarcinoma

A novel tumor-derived exosomal gene signature predicts prognosis in patients with pancreatic cancer

A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma

Prediction of the immunological and prognostic value of five signatures related to fatty acid metabolism in patients with cervical cancer

A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma

Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients

The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma